Market Overview:
The global viral inactivation market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth of this market is mainly driven by the increasing demand for blood and blood products, cellular and gene therapy products, stem cell products, tissue and tissue products, vaccines and therapeutics. In addition, the growing awareness about viral inactivation technologies among healthcare professionals is also contributing to the growth of this market. On the basis of type, the global viral inactivation market can be segmented into kits and reagents, services, viral inactivation systems and accessories. The kits and reagents segment accounted for the largest share of this market in 2017 owing to their wide use across various applications. On the basis of application, this market can be divided into blood and blood products; cellular and gene therapy products; stem cell products; tissueand tissueproducts; vaccinesand therapeutics.
Product Definition:
The definition of viral inactivation is the destruction or removal of a virus from a sample. It is important because it helps to ensure that any samples used in medical procedures are free from viruses.
Kits and Reagents:
Kits and reagents are the products used by laboratories to perform specific viral inactivation procedures. Kits and reagents are widely used across various end-use industries such as biotechnology, pharmaceuticals, research institutes, hospitals & clinics among others. The growth factor for kits and reagents is the rapid technological advancements that have led to an increase in usage of these products across various applications.
Services:
The services comprise of viral inactivation, hitachi autoclave sterilization and plating, scalability up-gradation and plate replication. Viral inactivation is the process of neutralizing or removing all viruses from a product with the help of detergents, disinfectants or chemical agents.
Application Insights:
Based on the application, the viral inactivation market is segmented into blood and blood products, cellular and gene therapy products, stem cell products, tissue and tissue products, vaccines and therapeutics. The blood and blood product segment dominated the overall market in terms of revenue share in 2017. This can be attributed to factors such as a high prevalence of infectious diseases that are transmitted through transfusion of contaminated materials which leads to an increased demand for viral inactivation solutions among other applications.
The cellular & gene therapy product segment is anticipated to witness lucrative growth over the forecast period owing to increasing usage of retroviral vectors for delivery purposes coupled with rising awareness regarding safety procedures during clinical trials involving these technologies.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of manufacturers, suppliers, and researchers working toward developing new therapies for treatment of viral diseases. The U.S.-based companies are involved in extensive research activities to identify and characterize novel targets for virus-specific therapy as well as develop effective vaccines against emerging viruses such as COVID-19.
The Asia Pacific is expected to grow at a lucrative rate over the forecast period owing to increasing R&D investments by various organizations along with rising healthcare expenditure levels in this region. Moreover, growing awareness about potential benefits associated with viral vector technology is anticipated to fuel regional growth during the forecast period from 2018 till 2030 (estimated). China has been observed making significant progress over past few years owing to its strong base of biotechnology industry coupled with government support towards development & approval processes for innovative products including therapeutic proteins & vaccines derived from live attenuated viruses (LAVs).
Growth Factors:
- Increasing demand for viral inactivation products and services from biopharmaceutical and medical device manufacturers to ensure the safety of their products.
- Growing awareness among healthcare professionals about the benefits of using viral inactivation technologies for preventing the spread of infections.
- Proliferation of new viral inactivation technologies that offer improved efficacy, speed, and flexibility over traditional methods.
- Rising number of mergers and acquisitions among players in the viral inactivation market as companies strive to expand their product portfolios and geographical reach.
- Increasing investments by government agencies and private organizations for research on novel virucidal agents and technologies
Scope Of The Report
Report Attributes
Report Details
Report Title
Viral Inactivation Market Research Report
By Type
Kits and Reagents, Services, Viral Inactivation Systems and Accessories
By Application
Blood and Blood Products, Cellular and Gene Therapy Products, Stem Cell Products, Tissue and Tissue Products, Vaccines and Therapeutics
By Companies
Danaher, Merck, Parker Hannifin, Sartorius, SGS, Charles River Laboratories International, Clean Cells, Rad Source Technologies, Texcell, Viral Inactivated Plasma Systems, Wuxi Pharmatech (Cayman)
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
155
Number of Tables & Figures
109
Customization Available
Yes, the report can be customized as per your need.
Global Viral Inactivation Market Report Segments:
The global Viral Inactivation market is segmented on the basis of:
Types
Kits and Reagents, Services, Viral Inactivation Systems and Accessories
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Blood and Blood Products, Cellular and Gene Therapy Products, Stem Cell Products, Tissue and Tissue Products, Vaccines and Therapeutics
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Danaher
- Merck
- Parker Hannifin
- Sartorius
- SGS
- Charles River Laboratories International
- Clean Cells
- Rad Source Technologies
- Texcell
- Viral Inactivated Plasma Systems
- Wuxi Pharmatech (Cayman)
Highlights of The Viral Inactivation Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Kits and Reagents
- Services
- Viral Inactivation Systems and Accessories
- By Application:
- Blood and Blood Products
- Cellular and Gene Therapy Products
- Stem Cell Products
- Tissue and Tissue Products
- Vaccines and Therapeutics
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Viral Inactivation Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Viral inactivation is a process by which viral DNA or RNA is destroyed. Viral inactivation can be achieved through various means, including heat, radiation, and chemicals.
Some of the major players in the viral inactivation market are Danaher, Merck, Parker Hannifin, Sartorius, SGS, Charles River Laboratories International, Clean Cells, Rad Source Technologies, Texcell, Viral Inactivated Plasma Systems, Wuxi Pharmatech (Cayman).
The viral inactivation market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Viral Inactivation Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Viral Inactivation Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Viral Inactivation Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Viral Inactivation Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Viral Inactivation Market Size & Forecast, 2018-2028
4.5.1 Viral Inactivation Market Size and Y-o-Y Growth
4.5.2 Viral Inactivation Market Absolute $ Opportunity
Chapter 5 Global Viral Inactivation Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Viral Inactivation Market Size Forecast by Type
5.2.1 Kits and Reagents
5.2.2 Services
5.2.3 Viral Inactivation Systems and Accessories
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Viral Inactivation Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Viral Inactivation Market Size Forecast by Applications
6.2.1 Blood and Blood Products
6.2.2 Cellular and Gene Therapy Products
6.2.3 Stem Cell Products
6.2.4 Tissue and Tissue Products
6.2.5 Vaccines and Therapeutics
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Viral Inactivation Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Viral Inactivation Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Viral Inactivation Analysis and Forecast
9.1 Introduction
9.2 North America Viral Inactivation Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Viral Inactivation Market Size Forecast by Type
9.6.1 Kits and Reagents
9.6.2 Services
9.6.3 Viral Inactivation Systems and Accessories
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Viral Inactivation Market Size Forecast by Applications
9.10.1 Blood and Blood Products
9.10.2 Cellular and Gene Therapy Products
9.10.3 Stem Cell Products
9.10.4 Tissue and Tissue Products
9.10.5 Vaccines and Therapeutics
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Viral Inactivation Analysis and Forecast
10.1 Introduction
10.2 Europe Viral Inactivation Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Viral Inactivation Market Size Forecast by Type
10.6.1 Kits and Reagents
10.6.2 Services
10.6.3 Viral Inactivation Systems and Accessories
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Viral Inactivation Market Size Forecast by Applications
10.10.1 Blood and Blood Products
10.10.2 Cellular and Gene Therapy Products
10.10.3 Stem Cell Products
10.10.4 Tissue and Tissue Products
10.10.5 Vaccines and Therapeutics
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Viral Inactivation Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Viral Inactivation Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Viral Inactivation Market Size Forecast by Type
11.6.1 Kits and Reagents
11.6.2 Services
11.6.3 Viral Inactivation Systems and Accessories
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Viral Inactivation Market Size Forecast by Applications
11.10.1 Blood and Blood Products
11.10.2 Cellular and Gene Therapy Products
11.10.3 Stem Cell Products
11.10.4 Tissue and Tissue Products
11.10.5 Vaccines and Therapeutics
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Viral Inactivation Analysis and Forecast
12.1 Introduction
12.2 Latin America Viral Inactivation Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Viral Inactivation Market Size Forecast by Type
12.6.1 Kits and Reagents
12.6.2 Services
12.6.3 Viral Inactivation Systems and Accessories
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Viral Inactivation Market Size Forecast by Applications
12.10.1 Blood and Blood Products
12.10.2 Cellular and Gene Therapy Products
12.10.3 Stem Cell Products
12.10.4 Tissue and Tissue Products
12.10.5 Vaccines and Therapeutics
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Viral Inactivation Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Viral Inactivation Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Viral Inactivation Market Size Forecast by Type
13.6.1 Kits and Reagents
13.6.2 Services
13.6.3 Viral Inactivation Systems and Accessories
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Viral Inactivation Market Size Forecast by Applications
13.10.1 Blood and Blood Products
13.10.2 Cellular and Gene Therapy Products
13.10.3 Stem Cell Products
13.10.4 Tissue and Tissue Products
13.10.5 Vaccines and Therapeutics
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Viral Inactivation Market: Competitive Dashboard
14.2 Global Viral Inactivation Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Danaher
14.3.2 Merck
14.3.3 Parker Hannifin
14.3.4 Sartorius
14.3.5 SGS
14.3.6 Charles River Laboratories International
14.3.7 Clean Cells
14.3.8 Rad Source Technologies
14.3.9 Texcell
14.3.10 Viral Inactivated Plasma Systems
14.3.11 Wuxi Pharmatech (Cayman)
